首页> 美国卫生研究院文献>Current Therapeutic Research Clinical and Experimental >Effects of lamotrigine monotherapy in patients with newly diagnosed juvenile myoclonic epilepsy: An open-label study
【2h】

Effects of lamotrigine monotherapy in patients with newly diagnosed juvenile myoclonic epilepsy: An open-label study

机译:拉莫三嗪单一疗法对新诊断的青少年肌阵挛性癫痫患者的影响:一项开放性研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Background:It is important that drug therapy for juvenile myoclonic epilepsy(JME), a lifelong disorder requiring long-term therapy, is effective and well tolerated with long-term use. Lamotrigine as monotherapy or adjunctive therapy has been demonstrated to be effective in reducing the frequency of partial and generalized seizures in short- and long-term studies in children, adolescents, adults, and elderly patients with epilepsy, including those with JME. With its tolerability profile and spectrum of efficacy, lamotrigine might be an appropriate option for newly diagnosed patients with JME, a possibility that has not been empirically assessed.
机译:背景:重要的是,对于青少年肌阵挛性癫痫(JME)(一种需要长期治疗的终生疾病),药物治疗必须有效且长期耐受,才能有效治疗。在儿童,青少年,成人和老年癫痫患者(包括JME患者)的短期和长期研究中,拉莫三嗪作为单一疗法或辅助疗法已被证明可有效减少部分和全身性癫痫发作的频率。凭借其耐受性特征和功效范围,拉莫三嗪对于新诊断的JME患者可能是合适的选择,这一可能性尚未经过经验评估。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号